secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001213900-22-079487
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed appoints interim CFO and replaces auditor KPMG with Marcum
----------------------------------------------------------------

- Jonathan Tegge appointed Interim CFO via Brio; monthly fee $9,750. Effective Dec 12, 2022.
- KPMG resigned as auditor (Dec 8, 2022); InMed engaged Marcum LLP as replacement, subject to acceptance.
- Annual Meeting Dec 15, 2022; management to recommend Marcum appointment using discretionary proxy.
- Options granted: 1,400 fully vested shares to Brio; 1,400 shares vesting monthly over 12 months to Tegge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/0001213900-22-079487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/ea170120-8k_inmedpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-079487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer